Welcome to LookChem.com Sign In|Join Free

CAS

  • or

149488-58-4

Post Buying Request

149488-58-4 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

149488-58-4 Usage

Description

1-(4-cyano-1,3-thiazol-2-yl)-3-[2-(2,6-difluorophenyl)ethyl]thiourea is a chemical compound with the molecular formula C14H12F2N4S2. It is a thiourea derivative known for its potential antiproliferative properties, which means it can inhibit the growth and spread of cancer cells. 1-(4-cyano-1,3-thiazol-2-yl)-3-[2-(2,6-difluorophenyl)ethyl]thiourea features a thiazole ring and a difluorophenyl group, both of which contribute to its biological activity. Its potential medicinal properties make it a promising candidate for further research and development in cancer treatment.

Uses

Used in Pharmaceutical Industry:
1-(4-cyano-1,3-thiazol-2-yl)-3-[2-(2,6-difluorophenyl)ethyl]thiourea is used as a potential antiproliferative agent for its ability to inhibit the growth and spread of cancer cells. Its unique structure, including the thiazole ring and difluorophenyl group, contribute to its effectiveness in this application.
Used in Cancer Treatment Research:
In the field of cancer treatment, 1-(4-cyano-1,3-thiazol-2-yl)-3-[2-(2,6-difluorophenyl)ethyl]thiourea is used as a subject of research to explore its potential as a new therapeutic agent. Its antiproliferative properties make it a valuable compound for investigating its effectiveness against various types of cancer.
Used in Drug Development:
1-(4-cyano-1,3-thiazol-2-yl)-3-[2-(2,6-difluorophenyl)ethyl]thiourea is also used in the development of new drugs, particularly those targeting cancer. Its potential medicinal properties and antiproliferative activity make it a promising candidate for the creation of novel therapeutic options in oncology.

Check Digit Verification of cas no

The CAS Registry Mumber 149488-58-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,4,9,4,8 and 8 respectively; the second part has 2 digits, 5 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 149488-58:
(8*1)+(7*4)+(6*9)+(5*4)+(4*8)+(3*8)+(2*5)+(1*8)=184
184 % 10 = 4
So 149488-58-4 is a valid CAS Registry Number.

149488-58-4SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 17, 2017

Revision Date: Aug 17, 2017

1.Identification

1.1 GHS Product identifier

Product name 1-(4-cyano-1,3-thiazol-2-yl)-3-[2-(2,6-difluorophenyl)ethyl]thiourea

1.2 Other means of identification

Product number -
Other names PETT 4-CN thiazol deriv.

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:149488-58-4 SDS

149488-58-4Downstream Products

149488-58-4Relevant articles and documents

Phenethylthiazolethiourea (PETT) compounds, a new class of HIV-1 reverse transcriptase inhibitors. 1. Synthesis and basic structure-activity relationship studies of PETT analogs

Bell,Cantrell,Hogberg,Jaskunas,Johansson,Jordan,Kinnick,Lind,Morin Jr.,Noreen,Oberg,Palkowitz,Parrish,Pranc,Sahlberg,Ternansky,Vasileff,Vrang,West,et al.

, p. 4929 - 4936 (2007/10/03)

A novel series of potent specific HIV-1 inhibitory compounds is described. The lead compound in the series, N-(2-phenethyl)-N'-(2-thiazolyl)thiourea (1), inhibits HIV-1 RT using rCdG as the template with an IC50 of 0.9 μM. In MT-4 cells, compound 1 inhibits HIV-1 with an ED50 of 1.3 μM. The 50% cytotoxic dose in cell culture is >380 μM. The chemical structure-activity relationship (SAR) was developed by notionally dividing the lead compound in four quadrants. The SAR strategy had two phases. The first phase involved optimization of antiviral activity through independent variation of quadrants 1-4. The second phase involved the preparation of hybrid structures combining the best of these substituents. Further SAR studies and pharmacokinetic considerations led to the identification of N-(2-pyridyl)-N'-(5-bromo-2- pyridyl)-thiourea (62; LY300046 · HCl) as a candidate for clinical evaluation. LY300046 · HCl inhibits HIV-1 RT with an IC50 of 15 nM and in cell culture has an ED50 of 20 nM.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 149488-58-4